retatrutide liver Since January 2026, there have been six cases of acute toxicity associated with unapproved peptide products labelled in Australia. These toxic effects may be linked to a contaminant in the Retatrutide Clears Fatty Liver Disease

The peptide protects the gut lining, reduces intestinal inflammation, and accelerates healing of damaged gut tissue

Advise patients that they will need to be monitored to see if impaired glucose tolerance or diabetes mellitus develops, and that if they have pre-existing diabetes mellitus, they may need adjustments to their anti-diabetic medications [see Warnings and Precautions (5.4)]

Between late 2023 and 2024, the FDA moved several popular peptides to the Category 2 list, citing concerns about insufficient human safety data and the potential for immunogenicity (the property of provoking an immune response)

Because the available evidence is largely preclinical, any benefits for androgenetic alopecia or other forms of hair loss in humans remain unproven